BITX (formerly IRX) is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer.
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.01.2015 | - | $31.6M | - |
| 24.05.2007 | - | $12.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 20.01.2015 | IRX Therapeutics raises $31.6M to start Phase 2B trials of its ‘generic’ immunity-boosting cancer drug | The company’s therapy ups the immune response of cancer patients, helping their innate defense systems better recognize and respond to tumors. In the process, this immunotherapy approach ostensibly helps patients immunize themselves against... |
| 05.06.2012 | Cancer immunotherapy firm raises $1.5M, eyes strategic partners | At least 40 additional unique cancer immunotherapies are currently being tested, according to a report from MD Becker Partners LLC, including ones developed by Bavarian Nordic, GlaxoSmithKline, Bristol-Myers Squibb, Oncothyreo/Merck and Tra... |
| 24.05.2007 | IRX Therapeutics raises $12.5M for cancer drugs | New York’s IRX Therapeutics, a developer of drugs designed to stimulate the immune system against viruses and cancer, raised $12.5 million in a second convertible note offering. The investors were mostly private individuals, including Frank... |
| - | IRX Therapeutics raises $31.6M to start Phase 2B trials of its ‘generic’ immunity-boosting cancer drug | New York biotech IRX Therapeutics just raised $31.6 million to finance later stage trials of its fast-tracked immunity-boosting cancer therapeutic, IRX-2.
The randomized head and neck cancer Phase 2B trial will study about 200 patients, wit... |
| - | Cancer immunotherapy firm raises $1.5M, eyes strategic partners | A company developing products to restore the immune system of cancer patients has raised $1.5 million and is now looking for strategic partners.
IRX Therapeutics’ lead product, IRX-2, aims to correct dendritic cell and T-cell defects in can... |
Reviews 0
